The medical field now uses transdermal bronchodilator patches as a separate method to handle asthma and chronic obstructive pulmonary disease (COPD). Such benefits together with enhanced patient compliance stem from transdermal patches because they enable controlled drug delivery while bypassing first-pass metabolism and maintaining stable plasma drug levels. The application of bronchodilator skin patches outperforms typical oral and inhaled medicines according to studies performed on living subjects. The technical and legal obstacles related to skin permeability limit its implementation because of stability problems along with strict approval processes. Nanotechnology developments merged with permeation enhancers along with smart patches present promising solutions for medical practice. Maximizing formulations and determining proper respiratory disease treatment positions for medications will require more research studies and clinical trials.